NDLI: The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.

Please wait, while we are loading the content...

Year: 2017 Volume: 39

Year: 2016 Volume: 38

Year: 2015 Volume: 37

Year: 2014 Volume: 36

Year: 2013 Volume: 35

Year: 2013 Volume: 35 Issue: 12

Year: 2013 Volume: 35 Issue: 11

Year: 2013 Volume: 35 Issue: 10

Year: 2013 Volume: 35 Issue: 9

Year: 2013 Volume: 35 Issue: 8

A cost-effectiveness analysis of parecoxib in the management of postoperative pain in the Greek health care setting.

Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population.

The bad taste of medicines: overview of basic research on bitter taste.

Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.

A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.

Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.

The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.

Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Acute coronary syndromes, seedless watermelons, and colchicine.

Acute coronary syndromes: much progress, new challenges.

Pros, cons, and organization of prehospital thrombolysis.

New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.

Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial.

Improving outcomes after acute coronary syndrome with rehabilitation and secondary prevention.

Targeting the unstable plaque in acute coronary syndromes.

Year: 2013 Volume: 35 Issue: 7

Year: 2013 Volume: 35 Issue: 6

Year: 2013 Volume: 35 Issue: 5

Year: 2013 Volume: 35 Issue: 4

Year: 2013 Volume: 35 Issue: 3

Year: 2013 Volume: 35 Issue: 2

Year: 2013 Volume: 35 Issue: 1

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Davidson, Michael
Description	Country affiliation: United States Author Affiliation: Davidson M ( University of Chicago, Pritzker School of Medicine, Chicago, IL 60611, USA. mdavidso@medicine.bsd.uchicago.edu)
Abstract	BACKGROUND: Familial hypercholesterolemia (FH) is a common autosomal co-dominant genetic disorder that results in severely increased levels of LDL-C. Patients with FH are at an increased risk for premature coronary artery disease. Expert panels therefore recommend initiation of lipid-lowering therapy in childhood to reduce the very high lifetime risk of coronary artery disease. The bile acid sequestrant colesevelam is indicated to reduce elevated LDL-C levels in adults with primary hyperlipidemia and in boys and postmenarchal girls (aged 10-17 years) with heterozygous FH. OBJECTIVE: The purpose of this article was to review currently available data on the use of colesevelam in the treatment of heterozygous FH. METHODS: PubMed and Google Scholar were searched to identify clinical trials evaluating colesevelam in patients with heterozygous FH. RESULTS: The search returned 2 results (both multicenter, multinational studies): 1 study conducted in adults and the other in pediatric patients. In the study in adults with refractory FH, the addition of colesevelam to a maximally tolerated regimen of a statin plus ezetimibe provided a significantly greater reduction from baseline in LDL-C levels compared with placebo. Significantly greater reductions from baseline in LDL-C were also seen in pediatric patients with heterozygous FH receiving colesevelam (alone or in combination with statins) compared with placebo. Colesevelam was generally well tolerated in studies in patients with FH; consistent with other colesevelam studies, gastrointestinal disorders were the most common drug-related adverse events, but these events rarely led to study withdrawal. CONCLUSIONS: Currently available data demonstrate that colesevelam, alone or in combination therapy, is efficacious and well tolerated in the treatment of heterozygous FH in adults and pediatric patients, supporting its use as a treatment option in both of these patient populations.
File Format	HTM / HTML
ISSN	01492918
Issue Number	8
Volume Number	35
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2013-08-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Allylamine Analogs & Derivatives Anticholesteremic Agents Therapeutic Use Hydroxymethylglutaryl-coa Reductase Inhibitors Hyperlipoproteinemia Type Ii Drug Therapy Adolescent Adult Aged Administration & Dosage Adverse Effects Azetidines Cholesterol, Ldl Blood Colesevelam Hydrochloride Coronary Artery Disease Complications Double-blind Method Drug Administration Schedule Drug Therapy, Combination Ezetimibe Female Gastrointestinal Diseases Chemically Induced Humans Male Middle Aged Young Adult Journal Article Randomized Controlled Trial Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in